JP2012532600A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012532600A5 JP2012532600A5 JP2012519079A JP2012519079A JP2012532600A5 JP 2012532600 A5 JP2012532600 A5 JP 2012532600A5 JP 2012519079 A JP2012519079 A JP 2012519079A JP 2012519079 A JP2012519079 A JP 2012519079A JP 2012532600 A5 JP2012532600 A5 JP 2012532600A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- amino acids
- isolated
- seq
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001413 amino acids Chemical class 0.000 claims description 149
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 149
- 229920001184 polypeptide Polymers 0.000 claims description 148
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 148
- 230000002163 immunogen Effects 0.000 claims description 58
- 239000012634 fragment Substances 0.000 claims description 37
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 32
- 102000004169 proteins and genes Human genes 0.000 claims description 31
- 108090000623 proteins and genes Proteins 0.000 claims description 31
- 108091033319 polynucleotide Proteins 0.000 claims description 14
- 102000040430 polynucleotide Human genes 0.000 claims description 14
- 239000002157 polynucleotide Substances 0.000 claims description 14
- 241000588724 Escherichia coli Species 0.000 claims description 12
- 230000028993 immune response Effects 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 7
- 239000013612 plasmid Substances 0.000 claims description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 description 11
- 230000037430 deletion Effects 0.000 description 11
- 101710109637 Antigen 43 Proteins 0.000 description 9
- 101710147195 Hemolysin A Proteins 0.000 description 9
- 206010022000 influenza Diseases 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 6
- 239000012528 membrane Substances 0.000 description 4
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 108050002207 TonB-dependent siderophore receptors Proteins 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 101150084252 gspJ gene Proteins 0.000 description 3
- 101150023725 gspK gene Proteins 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 241000588722 Escherichia Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22366409P | 2009-07-07 | 2009-07-07 | |
| US61/223,664 | 2009-07-07 | ||
| US29114009P | 2009-12-30 | 2009-12-30 | |
| US61/291,140 | 2009-12-30 | ||
| PCT/IB2010/001962 WO2011004263A2 (en) | 2009-07-07 | 2010-07-07 | Conserved escherichia coli immunogens |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012532600A JP2012532600A (ja) | 2012-12-20 |
| JP2012532600A5 true JP2012532600A5 (https=) | 2013-08-15 |
Family
ID=43429616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012519079A Withdrawn JP2012532600A (ja) | 2009-07-07 | 2010-07-07 | 保存された大腸菌免疫原 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10988511B2 (https=) |
| EP (1) | EP2451833B1 (https=) |
| JP (1) | JP2012532600A (https=) |
| CN (1) | CN102666571A (https=) |
| AU (1) | AU2010269961A1 (https=) |
| CA (1) | CA2767536A1 (https=) |
| ES (1) | ES2662716T3 (https=) |
| IL (1) | IL217412A0 (https=) |
| MX (1) | MX2012000395A (https=) |
| SG (1) | SG177533A1 (https=) |
| WO (1) | WO2011004263A2 (https=) |
| ZA (1) | ZA201200412B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2755994A2 (en) | 2011-09-14 | 2014-07-23 | Novartis AG | Escherichia coli vaccine combination |
| US20150086592A1 (en) * | 2013-09-25 | 2015-03-26 | Sequoia Sciences, Inc | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| CL2014001126A1 (es) * | 2014-04-29 | 2014-08-29 | Univ Chile | Composición farmacéutica útil como vacuna contra bacterias escherichia coli productoras de shigatoxinas (stec), que comprende al menos un antígeno o una proteína de membrana externa inmunogénica o proteína inmunogénica asociada y conservada en cepas stec. |
| US10759836B2 (en) * | 2014-07-18 | 2020-09-01 | University Of Washington | Cancer vaccine compositions and methods of use thereof |
| US10799573B2 (en) * | 2016-03-30 | 2020-10-13 | Regents Of The University Of Minnesota | Pertussis vaccines and methods of making and using |
| IL268626B2 (en) * | 2017-02-13 | 2024-04-01 | Alexandre Eduardo Nowill | Immunogenic composition for modulating the immune system and methods to treat bacterial infections in a subject |
| AU2019323944B2 (en) * | 2018-08-23 | 2026-04-16 | La Trobe University | Compositions and methods for reducing bacterial aggregation |
| EP3980056A4 (en) * | 2019-05-31 | 2023-03-29 | Universidad De Chile | IMMUNOGENIC FORMULATION THAT INDUCES PROTECTION AGAINST ESCHERICHIA COLI PRODUCING SHIGA TOXIN (STEC) |
| EP4121086A1 (en) * | 2020-03-18 | 2023-01-25 | NUMAFERM GmbH | Variants of hlya and uses thereof |
| EP3892290A1 (en) * | 2020-04-08 | 2021-10-13 | NUMAFERM GmbH | Variants of hlya and uses thereof |
| CN115466732B (zh) * | 2021-06-10 | 2024-09-03 | 宁夏医科大学 | 用于制备Hispidin的重组蛋白及其应用 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6090406A (en) | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
| US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
| US5011828A (en) | 1985-11-15 | 1991-04-30 | Michael Goodman | Immunostimulating guanine derivatives, compositions and methods |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US5206152A (en) | 1988-04-08 | 1993-04-27 | Arch Development Corporation | Cloning and expression of early growth regulatory protein genes |
| US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
| AU631377B2 (en) | 1988-08-25 | 1992-11-26 | Liposome Company, Inc., The | Affinity associated vaccine |
| WO1990007936A1 (en) | 1989-01-23 | 1990-07-26 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
| CA2489769A1 (en) | 1989-03-21 | 1990-10-04 | Philip L. Felgner | Expression of exogenous polynucleotide sequences in a vertebrate |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
| AU648261B2 (en) | 1989-08-18 | 1994-04-21 | Novartis Vaccines And Diagnostics, Inc. | Recombinant retroviruses delivering vector constructs to target cells |
| US4988815A (en) | 1989-10-26 | 1991-01-29 | Riker Laboratories, Inc. | 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines |
| ZA911974B (en) | 1990-03-21 | 1994-08-22 | Res Dev Foundation | Heterovesicular liposomes |
| US5658731A (en) | 1990-04-09 | 1997-08-19 | Europaisches Laboratorium Fur Molekularbiologie | 2'-O-alkylnucleotides as well as polymers which contain such nucleotides |
| US5149655A (en) | 1990-06-21 | 1992-09-22 | Agracetus, Inc. | Apparatus for genetic transformation |
| GB2276169A (en) | 1990-07-05 | 1994-09-21 | Celltech Ltd | Antibodies specific for carcinoembryonic antigen |
| WO1992011033A1 (en) | 1990-12-20 | 1992-07-09 | Arch Development Corporation | Control of gene expression by ionizing radiation |
| DE69229114T2 (de) | 1991-03-01 | 1999-11-04 | Minnesota Mining And Mfg. Co., Saint Paul | 1,2-substituierte 1h-imidazo[4,5-c]chinolin-4-amine |
| CA2138997C (en) | 1992-06-25 | 2003-06-03 | Jean-Paul Prieels | Vaccine composition containing adjuvants |
| EP1024198A3 (en) | 1992-12-03 | 2002-05-29 | Genzyme Corporation | Pseudo-adenoviral vectors for the gene therapy of haemophiliae |
| US5776468A (en) | 1993-03-23 | 1998-07-07 | Smithkline Beecham Biologicals (S.A.) | Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A |
| EP0705344B8 (en) | 1993-06-24 | 2006-05-10 | Advec Inc. | Adenovirus vectors for gene therapy |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| WO1995011700A1 (en) | 1993-10-29 | 1995-05-04 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
| GB9326174D0 (en) | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
| US5707829A (en) | 1995-08-11 | 1998-01-13 | Genetics Institute, Inc. | DNA sequences and secreted proteins encoded thereby |
| WO1997042338A1 (en) | 1996-05-06 | 1997-11-13 | Chiron Corporation | Crossless retroviral vectors |
| US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
| US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
| GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
| AU1145699A (en) | 1997-09-05 | 1999-03-22 | Smithkline Beecham Biologicals (Sa) | Oil in water emulsions containing saponins |
| GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
| IL137809A0 (en) | 1998-02-12 | 2001-10-31 | American Cyanamid Co | Pneumococcal and meningococcal vaccines formulated with interleukin-12 |
| US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
| WO1999052549A1 (en) | 1998-04-09 | 1999-10-21 | Smithkline Beecham Biologicals S.A. | Adjuvant compositions |
| NZ508013A (en) | 1998-05-07 | 2003-08-29 | Corixa Corp | Adjuvant composition for use with an antigen in a vaccine composition |
| US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
| GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
| KR100629028B1 (ko) | 1998-10-16 | 2006-09-26 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 애쥬번트 시스템 및 백신 |
| US20030130212A1 (en) | 1999-01-14 | 2003-07-10 | Rossignol Daniel P. | Administration of an anti-endotoxin drug by intravenous infusion |
| US6551600B2 (en) | 1999-02-01 | 2003-04-22 | Eisai Co., Ltd. | Immunological adjuvant compounds compositions and methods of use thereof |
| WO2000046147A2 (en) | 1999-02-03 | 2000-08-10 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
| HUP0202885A3 (en) | 1999-09-24 | 2004-07-28 | Smithkline Beecham Biolog | Vaccines |
| TR200200777T2 (tr) | 1999-09-24 | 2002-09-23 | Smithkline Beecham Biologicals S.A. | Polioksietilen alkil eteri veya esteriyle en az bir iyonik olmayan yüzey aktif maddeli adjuvant. |
| NZ517929A (en) | 1999-09-25 | 2004-02-27 | Univ Iowa Res Found | Immunostimulatory nucleic acids |
| US20010044416A1 (en) | 2000-01-20 | 2001-11-22 | Mccluskie Michael J. | Immunostimulatory nucleic acids for inducing a Th2 immune response |
| ATE448226T1 (de) | 2000-09-01 | 2009-11-15 | Novartis Vaccines & Diagnostic | Aza heterocyclische derivate und ihre therapeutische verwendung |
| DE60115069T2 (de) | 2000-09-11 | 2006-08-03 | Chiron Corp., Emeryville | Chinolinonderivate als tyrosin-kinase inhibitoren |
| AU2001294750C1 (en) | 2000-09-26 | 2008-09-18 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| EP1383918A4 (en) | 2001-04-03 | 2005-01-05 | Biosynexus Inc | ANIMAL MODEL FOR DARMPATHOGENE |
| DE60234375D1 (de) | 2001-09-14 | 2009-12-24 | Cytos Biotechnology Ag | VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG |
| WO2003035836A2 (en) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
| AP2004003069A0 (en) | 2001-11-27 | 2004-06-30 | Anadys Pharmaceuticals Inc | 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof. |
| WO2003082272A1 (en) | 2002-03-29 | 2003-10-09 | Chiron Corporation | Substituted benzazoles and use thereof as raf kinase inhibitors |
| AU2003251518B2 (en) | 2002-06-13 | 2009-07-02 | New York University | Synthetic C-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases |
| DE60333762D1 (de) | 2002-08-23 | 2010-09-23 | Novartis Vaccines & Diagnostic | Pyrrolverbindungen als glykogen synthase kinase 3 inhibitoren |
| US7521062B2 (en) | 2002-12-27 | 2009-04-21 | Novartis Vaccines & Diagnostics, Inc. | Thiosemicarbazones as anti-virals and immunopotentiators |
| CA2513655C (en) | 2003-01-21 | 2011-11-22 | Chiron Corporation | Use of tryptanthrin compounds for immune potentiation |
| GB0301554D0 (en) | 2003-01-23 | 2003-02-26 | Molecularnature Ltd | Immunostimulatory compositions |
| WO2004087153A2 (en) | 2003-03-28 | 2004-10-14 | Chiron Corporation | Use of organic compounds for immunopotentiation |
| RU2236257C1 (ru) | 2003-09-15 | 2004-09-20 | Косяков Константин Сергеевич | Синтетический иммуноген для терапии и профилактики злоупотреблений наркотическими и психоактивными веществами |
| US20060089264A1 (en) * | 2004-02-24 | 2006-04-27 | Seungok Hong | Method of heat treating HTc conductors in a large fabricated system |
| KR20110132416A (ko) | 2004-04-05 | 2011-12-07 | 화이자 프로덕츠 인코포레이티드 | 미세유체화된 수중유 유화액 및 백신 조성물 |
| US20070128183A1 (en) | 2004-04-27 | 2007-06-07 | Intercell Ag | Td antigens |
| JP2008530245A (ja) * | 2005-02-18 | 2008-08-07 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド | 尿路病原性菌株由来の抗原 |
| SI1858920T1 (sl) | 2005-02-18 | 2016-07-29 | Glaxosmithkline Biologicals S.A. | Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso |
| US7691368B2 (en) | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
| US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
| US8148055B2 (en) * | 2006-06-30 | 2012-04-03 | Infineon Technologies Ag | Method for developing a photoresist |
| EP2586790A3 (en) * | 2006-08-16 | 2013-08-14 | Novartis AG | Immunogens from uropathogenic Escherichia coli |
| WO2011080595A2 (en) * | 2009-12-30 | 2011-07-07 | Novartis Ag | Polysaccharide immunogens conjugated to e. coli carrier proteins |
-
2010
- 2010-07-07 US US13/382,906 patent/US10988511B2/en active Active
- 2010-07-07 EP EP10749686.1A patent/EP2451833B1/en active Active
- 2010-07-07 AU AU2010269961A patent/AU2010269961A1/en not_active Abandoned
- 2010-07-07 WO PCT/IB2010/001962 patent/WO2011004263A2/en not_active Ceased
- 2010-07-07 MX MX2012000395A patent/MX2012000395A/es not_active Application Discontinuation
- 2010-07-07 CA CA2767536A patent/CA2767536A1/en not_active Abandoned
- 2010-07-07 ES ES10749686.1T patent/ES2662716T3/es active Active
- 2010-07-07 CN CN2010800406195A patent/CN102666571A/zh active Pending
- 2010-07-07 JP JP2012519079A patent/JP2012532600A/ja not_active Withdrawn
- 2010-07-07 SG SG2012000931A patent/SG177533A1/en unknown
-
2012
- 2012-01-08 IL IL217412A patent/IL217412A0/en unknown
- 2012-01-18 ZA ZA2012/00412A patent/ZA201200412B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012532600A5 (https=) | ||
| JP2014504851A5 (https=) | ||
| CN101012458A (zh) | 表达系统 | |
| US12296000B2 (en) | SLAM polynucleotides and polypeptides and uses thereof | |
| Messner et al. | Occurrence, structure, chemistry, genetics, morphogenesis, and functions of S-layers | |
| Kumar et al. | Structural analysis and cross-protective efficacy of recombinant 87 kDa outer membrane protein (Omp87) of Pasteurella multocida serogroup B: 2 | |
| Schulze et al. | Translocation of Borrelia burgdorferi surface lipoprotein OspA through the outer membrane requires an unfolded conformation and can initiate at the C‐terminus | |
| JP2012532626A5 (https=) | ||
| Nye et al. | Vibrio cholerae H‐NS domain structure and function with respect to transcriptional repression of ToxR regulon genes reveals differences among H‐NS family members | |
| AU739641B2 (en) | Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof | |
| AU2011304942B2 (en) | Fusion protein SAmB, coding gene and application thereof | |
| CN105073989A (zh) | 免疫原性多肽表层表达双歧杆菌 | |
| EP2920203B1 (en) | Recombinant polypeptide construct comprising multiple enterotoxigenic escherichia coli fimbrial subunits | |
| Robinson et al. | Genetic engineering of Francisella tularensis LVS for use as a novel live vaccine platform against Pseudomonas aeruginosa infections | |
| Kim et al. | Oral administration of Lactococcus lactis expressing Helicobacter pylori Cag7-ct383 protein induces systemic anti-Cag7 immune response in mice | |
| CN103436550B (zh) | 一种菌影载体的构建方法 | |
| CN116514994B (zh) | 一种大肠杆菌多菌毛表位融合蛋白及其制备方法与应用 | |
| Kuebutornye et al. | Molecular cloning and bioinformatics analysis of t3ss inner membrane ring hrpq from Vibrio harveyi | |
| CN103910785B (zh) | 一种荧光假单胞菌TonB依赖型外膜受体及其应用 | |
| EP2908852B1 (en) | Lyme disease vaccine | |
| JP2023532415A5 (https=) | ||
| AU2017245737B2 (en) | Modifying bacteriophage | |
| JP2023510544A5 (https=) | ||
| JP6590916B2 (ja) | 毒素原性大腸菌およびジェジュニ菌の組合せの組換えコンストラクト | |
| KR101830792B1 (ko) | 항균 펩타이드를 포함하는 불용성 융합단백질 및 이를 이용한 항균 펩타이드의 제조 방법 |